Nexalin Technology, Inc. (NXL)
Nasdaq · Healthcare · Medical Devices
$5.43−5.24%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $4.5M
- 52-week range
- $4.00 – $60.00
- 52-week change
- −79.42%
- EPS (trailing)
- −$14.10
- Analyst rating
- 2.0 Buy
Fiscal year to Dec 2025
- Revenue
- $302K (+78.79%)
- Net income
- −$8.2M
- Operating margin
- −2781.7%
- Diluted EPS
- −$0.50
From the company’s annual report on SEC EDGAR.
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Headquarters: Houston, United States · 8 employees · nexalin.com